CM4620 to lessen pancreatitis after asparaginase
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy clinical trials.
This study tests CM4620 to reduce how severe pancreatitis becomes in children and young people with leukemia/lymphoma who develop pancreatitis after receiving a drug called asparaginase. It aims to improve outcomes by calming the inflammation of the pancreas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age under 22 and being treated for leukemia/lymphoma with the goal of cure
- Have acute pancreatitis, confirmed by blood tests (amylase or lipase) and/or symptoms/imaging
- Have taken any form of asparaginase within the last 49 days
- Do not have had pancreatitis before (no prior pancreatitis history)
- Baseline heart rhythm test (QTc) must not be too prolonged (not >450 ms)
- Cannot be pregnant or breastfeeding, and must use effective birth control if able to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called SGC001 given as an injection to people with severe acute pancreatitis, a serious inflammation of the pancreas. The study aims to see if the drug is safe and helpful, and to gather early information on how it works.
This trial tests a new treatment that uses light to activate a drug attached to cancer cells, aiming to destroy them during surgery. It is for people with pancreatic cancer that has not spread and who have already had chemotherapy.
This trial tests if taking aspirin daily can prevent repeated attacks of acute pancreatitis. It's for people who have had at least two episodes of pancreatitis in the past year that were not caused by a medical procedure.
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
This trial tests whether a drug called tacrolimus can reduce the risk of pancreatitis (inflammation of the pancreas) after a procedure called ERCP, which is used to diagnose and treat problems in the bile ducts or pancreas. If you are scheduled for an ERCP, this study may help prevent a common complication.
Hear when a new Acute Pancreatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.